SynthesisThe American journal of tropical medicine and hygiene2018
Impact of a Nonfatal Dengue Episode on Disability-Adjusted Life Years: A Systematic Analysis.
Synthesis in The American journal of tropical medicine and hygiene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.Emerging microbes & infections · 2026Review
- The cost-effectiveness of Wolbachia-based biocontrol interventions for dengue: A scoping review of the available evidence.PLoS neglected tropical diseases · 2026Article
- Health-related quality of life and associated factors among hospitalized dengue patients in Bangladesh: a cross-sectional study.BMC infectious diseases · 2026Observational
- From promise to pitfalls: immunological lessons from dengue vaccines and their implications.NPJ vaccines · 2026Review
- Guiding vaccine policy for chikungunya in Brazil: a cost-effectiveness analysis of live-attenuated versus recombinant chikungunya vaccines in Brazilian adults ≥18 years.BMJ public health · 2026Article
- Cost-effectiveness of chikungunya vaccination with the live attenuated vaccine in U.S. territories.NPJ vaccines · 2025Article
- Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.PLoS medicine · 2025Article
- Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement.PLoS neglected tropical diseases · 2025Article
- Article
- Estimating dengue disease and economic burden to inform municipal-level policymakers: Method for a pragmatic city-level observational cohort study.Gates open research · 2024Observational
- Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing: Pilot prospective observational study.Health science reports · 2023Article
- An economic evaluation of Wolbachia deployments for dengue control in Vietnam.PLoS neglected tropical diseases · 2023Article
- Is new dengue vaccine efficacy data a relief or cause for concern?NPJ vaccines · 2023Review
- Article
- An economic evaluation of implementing a decentralized dengue screening intervention under the National Vector Borne Disease Control Programme in Tamil Nadu, South India.International health · 2022Article
- Cost-effectiveness of dengue vaccination in Puerto Rico.PLoS neglected tropical diseases · 2021Article
- Cost of Dengue Illness in Indonesia across Hospital, Ambulatory, and not Medically Attended Settings.The American journal of tropical medicine and hygiene · 2020Article
- Dengue mouse models for evaluating pathogenesis and countermeasures.Current opinion in virology · 2020Review
- Measuring health related quality of life for dengue patients in Iquitos, Peru.PLoS neglected tropical diseases · 2020Article
- Estimating the burden of dengue and the impact of release of wMel Wolbachia-infected mosquitoes in Indonesia: a modelling study.BMC medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As dengue causes about 4,000 symptomatic nonfatal episodes for every dengue death globally, quantitative disability assessments are critical to assess the burden of dengue and the cost-effectiveness of dengue control interventions. This systematic analysis of disability or quality of life lost from a symptomatic nonfatal dengue episode combined a systematic literature review, statistical modeling, and probabilistic sensitivity analyses. We conceptualized a dengue episode as having two phases: acute and persistent symptoms. Our estimates for the acute phase, consisting of onset and recovery periods and defined as the first 20 days (0.054 year), were based on literature review. We searched PubMed, POPLINE, EconLit, Google Scholar, scientific conferences, and other sources, for "dengue" plus "quality of life" or related terms. From 4,322 initial entries, six met our criteria (original studies with empirical data). The median disability-adjusted life year (DALY) burden for the acute phase was 0.011 (95% certainty interval [CI]: 0.006-0.015) for ambulatory episodes, 0.015 (CI: 0.010-0.020) for hospitalized episodes, and 0.012 (CI: 0.006-0.019) overall. Using literature reviews about persistent dengue, we estimated that 34% of episodes experienced persistent symptoms with a median duration of symptoms of 0.087 (CI: 0.040-0.359) year, which resulted in median DALYs of 0.019 (CI: 0.008-0.082). Thus, the overall median DALY burden was 0.031 (CI: 0.017-0.092) for ambulatory episodes, 0.035 (CI: 0.024-0.096) for hospitalized episodes, and 0.032 (CI: 0.018-0.093) overall. Our dengue-specific burden of a dengue episode was 2.1 times the 2013 Global Burden of Disease estimate. These literature-based estimates provide an empirical summary for policy and cost-effectiveness analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.